Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH

• Status: Terminated
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate the effects of Rosiglitazone, insulin sensitizer and alpha-lipoic acid, antioxidant on patients with pathologically proved NASH (non-alcoholic steato-hepatitis).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul St. Mary's Hospital
• Collaborator: GlaxoSmithKline
• Treatments: Rosiglitazone; Thioctic Acid

Criteria

Inclusion Criteria:

• the patients with pathologically proved NASH (non-alcoholic steato-hepatitis)

Exclusion Criteria:

• alcohol consumption > 20g/day

• viral hepatitis B and C

• autoimmune hepatitis

• Wilson's disease

• hemochromatosis

• alpha-1 antitrypsin deficiency

• breast-feeding or pregnant females

• subjects planning to become pregnant

• severe comorbid medical conditions (such as severe cardiac, pulmonary, renal or psychological problems)

• those not consenting for the study